Dr Reddy’s inks or expands a licensing arrangement with Gilead to develop and sell lenacapavir-based HIV prevention, according to two reports. One outlet says the deal covers a once-yearly regimen, while another describes expansion of the pact related to an investigational HIV prevention product.
Both reports frame lenacapavir within a broader prevention landscape. They note that lenacapavir is used as a twice-yearly approach and that this schedule is already approved by major regulators, including the US Food and Drug Administration and the European Medicines Agency. They also cite WHO guidance recommending twice-yearly lenacapavir for HIV prevention.
The outlets differ mainly in emphasis: one highlights the specific timing of the licensing scope as once-yearly, while the other emphasizes that the agreement relates to an investigational prevention option and situates it alongside the already approved twice-yearly regimen. Neither account details the full commercial terms in the provided excerpts.
